Evidence map›Paper›PMID 35343054›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.

Pamela A Christopherson, Sandra L Haberichter, Veronica H Flood, Crystal L Perry, Brooke E Sadler, Daniel B Bellissimo, Jorge Di Paola, Robert R Montgomery, Zimmerman Program Investigators

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Challenges and considerations of genetic testing in von Willebrand disease.Research and practice in thrombosis and haemostasis · 2025
    Review
  6. Review
  7. Article
  8. Application of genetic testing for the diagnosis of von Willebrand disease.Journal of thrombosis and haemostasis : JTH · 2024
    Review
  9. von Willebrand disease.Nature reviews. Disease primers · 2024
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Pamela A ChristophersonVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.ORCID 0000-0001-6758-9815
Sandra L HaberichterVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Veronica H FloodVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Crystal L PerryVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Brooke E SadlerDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Daniel B BellissimoDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jorge Di PaolaDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-1461-2871
Robert R MontgomeryVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Zimmerman Program Investigators
Children's Hospital of Wisconsin · USVersiti Blood Center of Wisconsin · USWashington University in St. Louis · USUniversity of Pittsburgh · US

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
VWF - Mechanisms of RegulationR01HL136430 · NHLBI · VERSITI WISCONSIN, INC. · PI HABERICHTER, SANDRA · 2018 to 2021
$1.7M
NHLBI NIH HHS P01 HL081588NHLBI NIH HHS P01HL081588NHLBI NIH HHS P01 HL144457NHLBI NIH HHS P01HL144457NHLBI NIH HHS R01 HL136430NHLBI NIH HHS R01HL136430-01A1
6 · The paper itself

Abstract

backgroundType 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF).

objectivesAs part of the Zimmerman Program, we sought to explore the molecular pathogenesis, correlate bleeding phenotype and severity, and determine the inheritance pattern found in type 3 VWD families. PATIENTS/

methods62 index cases with a pre-existing diagnosis of type 3 VWD were analyzed. Central testing included FVIII, VWF:Ag, VWF:RCo, and VWFpp. Bleeding symptoms were quantified using the ISTH bleeding score. Genetic analysis included VWF sequencing, comparative genomic hybridization and predictive computational programs.

results75% of subjects (46) had central testing confirming type 3, while 25% were re-classified as type 1-Severe or type 1C. Candidate VWF variants were found in all subjects with 93% of expected alleles identified. The majority were null alleles including frameshift, nonsense, splice site, and large deletions, while 13% were missense variants. Additional studies on 119 family members, including 69 obligate carriers, revealed a wide range of heterogeneity in VWF levels and bleeding scores, even amongst those with the same variant. Co-dominant inheritance was present in 51% of families and recessive in 21%, however 28% were ambiguous.

conclusionThis report represents a large cohort of VWD families in the U.S. with extensive phenotypic and genotypic data. While co-dominant inheritance was seen in approximately 50% of families, this study highlights the complexity of VWF genetics due to the heterogeneity found in both VWF levels and bleeding tendencies amongst families with type 3 VWD.

Indexed as

von Willebrand Diseasesvon Willebrand Disease, Type 3Comparative Genomic HybridizationHemorrhageHumansPhenotypevon Willebrand Factorvon Willebrand Factorbleedinggenotype-phenotype associationinherited blood coagulation disorderstype 3 VWD

Identifiers

PMID35343054
PMCPMC11892521
OpenAlexW4221063410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.